

Original Article

PULMONARY FUNCTION TESTS AND THEIR REVERSIBILITY IN SMOKERS

Ghanshyam B Borisagar¹, Jayant B Chauhan²**Financial Support:** None declared**Conflict of interest:** None declared**Copy right:** The Journal retains the copyrights of this article. However, reproduction of this article in the part or total in any form is permissible with due acknowledgement of the source.**How to cite this article:**

Borisagar B, Chauhan JB. Pulmonary Function Tests and Their Reversibility in Smokers. Natl J Community Med 2014; 5(1): 122-125.

Author's Affiliation:¹Associate Professor, TB & Chest Department, PDU Government Medical College, Rajkot, India; ²Associate Professor, Tb & Chest Dept., GMERS Medical College, Sola, Ahmedabad, India**Correspondence:**Dr. Ghanshyam B Borisagar
Email: gbborisagar@yahoo.co.in**Date of Submission:** 08-02-14**Date of Acceptance:** 04-03-14**Date of Publication:** 31-3-14

ABSTRACT

Background: Smoking is known as the major cause of chronic obstructive pulmonary disease (COPD) where most of pulmonary function tests (PFTs) especially those indicating the diameter of airways are reduced. In this study, PFTs of smokers were compared with those of nonsmokers, and the effect of bronchodilator inhaler (salbutamol) on PFTs of smokers was also examined.**Methods:** Pulmonary function tests were measured in 97 male smokers and compared with 95 male nonsmokers. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), maximal mid-expiratory flow (MMEF), peak expiratory flow (PEF), maximal expiratory flow at 75%, 50%, and 25% of the FVC (MEF75, MEF50, and MEF25 respectively) were measured. In addition, pulmonary function tests of 33 male smokers before and 10 minutes after administration of 200 µg salbutamol inhaler were measured.**Results:** Most values of PFTs in smokers were significantly lower than those of non-smokers ($p < 0.001$ for FVC, FEV1, PEF, MEF75, $p < 0.01$ for MMEF, and $p < 0.02$ for MEF50). Significant correlations between the smoking duration and FEV1, PEF, MEF75, and MEF50 ($p < 0.05$ to $p < 0.01$) was found, but correlations between smoking quantity and values of PFTs were not significant. All values of PFTs were significantly increased after salbutamol administration ($p < 0.05$ to $p < 0.01$).**Conclusion:** The profound effect of smoking on PFT showed that smoking leads to constriction of large and medium sized airways which is mostly due to duration not to quantity of smoking. The airway constriction in smokers was reversible which, was mostly seen for medium sized airways.**Key words:** Pulmonary function tests, Smoking, Reversibility, Smoking duration, Smoking quantity

INTRODUCTION

It is observed that Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity throughout the world. A large number of people suffer from this disease for years and die prematurely from it or its complications. COPD is currently the fourth leading cause of death in the world¹, and further increases in its prevalence and mortality can be predicted in the coming decades.²

Long term use of Cigarette smoking is the most important risk factor for COPD and the most important way that tobacco contributes to the risk of COPD.³ Cigarette smokers have a higher prevalence of respiratory symptoms, pulmonary function abnormalities, greater annual rate of decline in FEV1, and a greater COPD mortality rate than those of non-smokers.⁴ These differences between cigarette smokers and non-smokers

increase in direct proportion to the quantity of smoking. Smoking leads to rapid decline in pulmonary function tests (PFTs) specially those indicating diameter of airways such as forced expiratory flow in one second (FEV1).⁵ Even in teenagers who have smoked only a few years, maximum expiratory flow-volume curves demonstrate decreases in flow rates at small lung volumes.⁶ If smoking causes changes in small airway caliber at such an early age, one might expect that smoking also causes acute changes in these small airways.

Until now, the only well-documented acute effect of smoking on the airways was the decrease of airway conductance demonstrated by Nadel and Comroe.⁷ The obstruction to airflow that develops in 15 to 20% of heavy smokers is thought to be due to abnormalities in airways with less than 2 mm internal diameter.⁸ Previous studies from several laboratories have shown

that this airway obstruction is associated with chronic inflammatory process in the membranous and respiratory bronchioles.^{9, 10} It is believed that the airway constriction in COPD and decline in PFT are not reversible. Therefore, in the present study the pulmonary function tests of smokers were compared with those of non-smokers. The effect of quantity and duration of smoking on PFT and the reversibility of PFT were also evaluated in the present study.

MATERIAL AND METHODS

Subjects: Ninety seven smokers (age 36.49±13.06, range 19-71 years old and height 171.71±6.68 range 158- 190) and ninety five non-smoker men (age 35.56±12.83, range 18-65 years old and height 171.79±8.81 range 154-194) were randomly selected from the visitor of our tertiary care centre (Table 1). All subjects had no history or symptoms of cardiovascular or respiratory diseases that required treatment (excluding the common cold). The protocol was approved by the "Ethics Committee" of our institution, and each subject gave informed consent. Measurement Expiratory flow-volume curves were recorded by a spirometer. The spirometer was calibrated daily for few days at the beginning, at the end and a few intervals during the middle of the study. However, because there were almost no differences in daily calibrations, calibration of the spirometer was carried out weekly in the rest of the study. All tests were conducted by a researcher who was fully trained regarding the procedure of spirometry. Prior to testing, the required manoeuvre was demonstrated by the operator, and subjects were encouraged and supervised throughout the test performance. Studies were performed using the acceptability standards outlined by the "American Thoracic Society" (ATS) with subjects in a standing position and wearing nose clips.¹¹ All tests were carried out between 1000 and 1700 hours. In 33 smokers, PFTs were repeated 10 min after 200 µg inhaled salbutamol. Pulmonary function tests were performed three times in each subject with an acceptable technique.

The highest level for forced vital capacity (FVC), forced expiratory volume in one second (FEV1), maximal mid-expiratory flow (MMEF), peak expiratory flow (PEF), and maximal expiratory flow at 75%, 50%, and 25% of the FVC (MEF75, MEF50, and MEF25 respectively) were taken independently from the three curves.

Data analysis: The data of height, age, and pulmonary function parameters were expressed as mean±SD. PFTs of smokers were compared with those of non-smokers using unpaired t-test. PFTs obtained after inhaled salbutamol were compared with the baseline values using paired t-test. The duration and quantity of smoking were related to decrease in their PFT values, using the least square regression. The criterion of significance was p<0.05.

RESULTS

Duration and quantity of smoking: Mean duration of smoking was 17.41±4.68 years (range 2-50 years) and mean quantity of smoking was 12.09±9.68 cigarettes per day (range 0.25-50), (Table1).

Pulmonary function tests: All values of pulmonary function tests in smokers were significantly lower than those of nonsmoker subjects (p<0.02 to P<0.001) except MEF25 (Table- 2).

Correlation between duration and quantity of smoking with PFTs in smokers: There were significant negative correlation between duration of smoking and decrease in FEV1, PEF, MEF75, and MEF50 (p<0.05 to p<0.01). However, the correlations between the quantity of smoking and values of PFT were not significant.

Low PFTs among smoker and nonsmoker subjects: The percentage of low values of most PFTs (lower than 80% predictive values) among smoker was significantly more than those of normal subjects (Table 3). Only 0-10.6% of non-smokers had low PFT values while in 21.6-42.3% of smokers PFT values were lower than normal range.

Table 1: Characteristics of study population

Variables	Non Smokers (n=95)		Smokers (n=97)	
	Range	Mean±SD	Range	Mean ±SD
Height (cm)	154-194	171.79±8.81	158-190	171.71±6.68
Age (year)	18-65	35.56±12.83	19-71	36.49±13.06
Amount (cigarettes per day)			0.25-50	12.09±9.68
Duration (years)			2-50	17.41±9.68
FVC	71.36-134.50	95.71±12.22	24-126	83.78±16.83
FEV1	80.90-184.40	102.04±17.29	15-130	89.80±16.80
MMEF	69.70-239.60	104.15±20.33	8-158	92.51±27.19
PEF	61.50-150.90	100.13±16.84	5-151	85.88±24.72
MEF75	51.50-170.50	105.62±21.65	6-170	90.01±29.07
MEF50	52.10-213.30	104.28±28.89	12-196	94.70±30.36
MEF25	68.50-223.80	110.48±27.58	36-257	110.84±42.42

FEV1: forced expiratory volume in one second; FVC: forced vital capacity; MMEF: maximal mid-expiratory flow; PEF: peak expiratory flow; MEF75, MEF50, and MEF25: maximal expiratory flow at 75%, 50%, and 25% of the FVC, respectively.

All values of PFTs were quoted as percentage predicted.

Effect of salbutamol on PFTs of smokers

Pulmonary function tests of 33 male smokers (height 172.79±11.94 cm, age 38.30±6.65 years) before and 10 min. after administration of 200 µg salbutamol inhaler were measured. All values of PFT in smokers significantly increased 10 min. after 200 µg inhaled salbutamol (p< 0.005). The enhancement in PEF, MEF75, and MEF50, was around 12% and that of MEF25 was 17% (Table 4).

Table 2: Pulmonary function tests (PFTs) among smoker and nonsmoker subjects

PFTs	Non Smokers#	Smokers#	P vALUE
FVC	95.71±12.22	83.78±16.83	P<0.001
FEV1	102.04±17.29	89.80±16.80	P<0.001
MMEF	104.15±20.33	92.51±27.19	P<0.01
PEF	100.13±16.84	85.88±24.72	P<0.001
MEF75	105.62±21.65	90.01±29.07	P<0.001
MEF50	104.28±94.70	94.70±30.36	P<0.05
MEF25	110.48±27.58	110.84±42.42	>0.05*

*NS=Not significant #figures in Mean±SD

Table 3: The percentage and range of low PFTs (lower than 80% predicted values among smoker and non-smoker subjects

PFTs	Non smokers				Smokers				Statistical difference
	Mean±SD	Range	Age	N	Mean±SD	Range	Age	n	
FVC	74.00±2.4	71-79	19-44	10	69.39±10.2	24-79	20-71	41	p<0.05
FEV1	--	--	--	--	68.27±14.4	15-79	21-71	22	--
MMEF	73.75±3.3	69-76	29-45	4	68.06±15.0	8-78	21-68	33	NS*
PEF	72.20±5.9	61-78	22-64	11	61.14±17.2	5-79	19-68	36	P<0.01
MEF75	65.38±11.2	51-78	22-64	8	60.69±18.7	6-79	19-71	32	NS*
MEF50	68.11±10.0	52-79	22-49	9	64.48±14.5	12-79	21-68	31	NS*
MEF25	72.56±3.2	68-78	23-63	8	64.71±10.7	36-79	21-53	24	P<0.05

*NS=Not significant

Table 4: Pulmonary function tests (PFTs) of smoker subjects before and 10 min. after inhalation of 200 µg salbutamol

PFTs	Before	After	P value
FVC(l)	76.76±13.23	81.68±16.32	P<0.001
FEV1(l)	82.79±12.79	90.62±14.74	P<0.001
MMEF(l/s)	80.74±19.07	90.03±24.09	P=0.002
PEF(l/s)	76.63±19.00	86.91±18.13	P<0.001
MEF75(l/s)	79.79±20.43	93.47±18.40	P<0.001
MEF50(l/s)	81.15±19.60	93.32±21.40	P<0.001
MEF25(l/s)	97.25±36.03	114.09±45.65	P=0.005

DISCUSSION

This study has shown reduction of all values of pulmonary function test values in smokers as compared to those nonsmoker subjects. Although the mean values of PFTs in smokers was in normal range (83.78±16.83 to 110.84±42.42), they were significantly lower than PFT values in normal subjects. However, in 21.6-42.3 % of smokers, the values of PFT were lower than normal range, while only 0-10.6% of normal subjects had low values of PFT. In addition, relatively younger smoker subjects had low values of PFT compared to normal subjects. Previous studies¹²⁻²⁰ also showed reduction of different values of PFT among smokers comparing to normal subjects.

The result of the present study showed the reduction in PEF and MEF75 among smoker subjects was significantly more than other values of PFT. These results may indicate that in smoker subjects medium and large airways are affected more than other airways. The results of our study were supported by previous studies indicating reduction of PFTs in smokers.¹⁷⁻¹⁸ However, there is some evidence that small airways are affected more by smoking.¹⁴ The results of the

present study also showed negative correlation between decrease in most values of PFT and duration of smoking.

However, the relationships between decrease in PFTs and quantities of smoking were not significant. These results showed that duration of smoking has more profound effect on airways than quantity of smoking. The studies of Sherrill et al.²¹ and Verschakelen et al.²² also showed correlation between smoking and reduction in most values of PFT which support the results of the present study. In addition, Burrows et al. also showed quantitative relationship between cigarette smoking and reduction in values of PFT.⁵

Furthermore, the results of the present study, showed that the values of PFT of smokers were significantly increased due to 200 µg inhaled salbutamol indicating some degree of reversibility of the airway constriction in smokers. Although the mean value of MEF25 among smokers was normal, increase in this value of PFT due to salbutamol administration was more than other values of PFT. This may indicate that in smokers small airways are more liable to reversible constriction. It is believed that airway constriction of COPD patients is not reversible, or there is very small reversibility of airways in these patients. However, the results of our study demonstrated a relatively large component of reversibility of airways in smokers, which is a novel finding of the present study.

CONCLUSION

The results of the present study demonstrated the profound effect of smoking on PFT and therefore, indicated that smoking leads to constriction of large and

medium airways, which is mostly due to duration, not to quantity of smoking. The airway constriction in smokers was reversible which was mostly seen for medium and small sized airways.

REFERENCES

1. World Health Organization. World health report. Geneva: WHO; 2000.
2. Murray CJ, Lopez AD. Evidence-based health policy-- lessons from the Global Burden of Disease Study. *Science* 1996; 274(5288): 740-3.
3. Auerbach O, Hammond EC, Garfinkel L, Benante C. Relation of smoking and age to emphysema. Whole-lung section study. *N Engl J Med* 1972; 286(16): 853-7.
4. Lebowitz MD, Burrows B. Quantitative relationships between cigarette smoking and chronic productive cough. *Int J Epidemiol* 1977; 6(2): 107-13.
5. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. *Am Rev Respir Dis* 1977; 115(2): 195-205.
6. Seely JE, Zuskin E, Bouhuys A. Cigarette smoking: objective evidence for lung damage in teen-agers. *Science* 1971; 172(984): 741-3.
7. Nadel JA, Comroe JH Jr. Acute effects of inhibition of cigarette smoke on airway conduction. *J Appl Physiol* 1961; 16: 713-6.
8. Hogg JC, Macklem PT, Thurlbeck MW. Site and nature of airway obstruction in chronic obstructive lung disease. *N Engl J Med* 1968; 278(25): 1355-60.
9. Berend N, Wright JL, Thurlbeck MW, Marlin GE, Woolcock AJ. Small airways disease: reproducibility of measurements and correlation with lung function. *Chest* 1981; 79(3): 263-8.
10. Wright JL, Lawson LM, Pare PD, Kennedy S, Wiggs B, Hogg JC. The detection of small airways disease. *Am Rev Respir Dis* 1984; 129(6): 989-94.
11. Standardization of spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med* 1995; 152(3): 1107-36.
12. Zuskin E, Mitchell CA, Bouhuys A. Interaction between effects of beta blockade and cigarette smoke on airways. *J Appl Physiol* 1974; 36(4): 449-52.
13. Lange P, Groth S, Nyboe GJ, Mortensen J, Appleyard M, Jensen G, Schnohr P. Effects of smoking and changes in smoking habits on the decline of FEV1. *Eur Respir J* 1989; 2(9): 811-6.
14. Bosken CH, Wiggs BR, Pare PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. *Am Rev Respir Dis* 1990; 142(3): 563-70.
15. Eidelman DH, Ghezzi H, Kim WD, Hyatt RE, Cosio MG. Pressure-volume curves in smokers. Comparison with alpha-1-antitrypsin deficiency. *Am Rev Respir Dis* 1989; 139(6): 1452-8.
16. Aparici M, Fernandez Gonzalez AL, Alegria E. Respiratory function tests. Differences between smokers and nonsmokers. Effects of withdrawal. *Rev Clin Esp* 1993; 192(4): 169-72.
17. Nemery B, Moavero NE, Brasseur L, Stanescu DC. Changes in lung function after smoking cessation: an assessment from a cross-sectional survey. *Am Rev Respir Dis* 1982; 125(1): 122-4.
18. Lubinski W, Targowski T, Frank-Piskorska A. Evaluation of the influence of tobacco smoking on pulmonary function in young men. *Pneumonol Alergol pol* 2000; 68(5-6): 226-31.
19. Goodman RM, Yergin BM, Landa JF, Golivanux MH, Sackner MA. Relationship of smoking history and pulmonary function tests to tracheal mucous velocity in nonsmokers, young smokers, ex-smokers, and patients with chronic bronchitis. *Am Rev Respir Dis* 1978; 117(2): 205-14.
20. Welty C, Weiss ST, Tager IB, Munoz A, Becker C, Speizer FE, Ingram RH Jr. The relationship of airways responsiveness to cold air, cigarette smoking, and atopy to respiratory symptoms and pulmonary function in adults. *Am Rev Respir Dis* 1984; 130(2): 198-203.
21. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Longitudinal methods for describing the relationship between pulmonary function, respiratory symptoms and smoking in elderly subjects: the Tucson Study. *Eur Respir J* 1993; 6(3): 342-8.
22. Verschakelen JA, Scheinbaum K, Bogaert J, Demedts M, Lacquet LL, Baert AL. Expiratory CT in cigarette smokers: correlation between areas of decreased lung attenuation, pulmonary function tests and smoking history. *Eur Radiol* 1998; 8(8): 1391-9.